Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: A double-blind randomised study

Lancet

Volumn 356, Issue 9226, 2000, Pages 273-278

  Tamaoki, J ^a   Kondo, M ^a   Sakai, N ^b   Aoshiba, K ^f   Tagaya, E ^d   Nakata, J ^c   Isono, K ^e   Nagai, A ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^c KUREHA CORPORATION   (Japan)

^d Nagashio Hospital   (Japan)

^e Saiseikai Kurihashi Hospital   (Japan)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN E; STEROID; SUPLATAST TOSYLATE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

EID: 0034702534     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02501-0     Document Type: Article

References (23)

1. Kon O.M., Kay A.B. T cells and chronic asthma. Int Arch Allergy Immunol. 118:1999;133-135.
2. Street N.E., Mosmann T.R. Functonal diversity of T-lymphocytes due to secretion of different cytokine patterns. FASEB J. 5:1991;171-177.
3. Kung T.T., Stelts D.M., Zurcher J.A.et al. Involvement of IL-5 in a murine model of allergic pulmonary infiltration. prophylactic and therapeutic effect of anti-IL-5 antibody Am J Respir Cell Mol Biol. 13:1995;360-365.
4. Coyle A.J., LeGros G., Bertrant C.et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 13:1995;54-59.
5. Brusselle G., Kips J., Joos G., Bluethmann H., Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol. 12:1995;254-259.
6. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, air-ways hyperreactivity and lung damage in a mouse asthma model. J Exp Med. 183:1996;195-210.
7. National Heart, Lung, and Blood Institute and World Health Organization. Global initiative for asthma. Bethesda, MD: National Institutes of Health pub no 95-3659, 1995.
8. National Asthma Education and Prevention Program. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health pub no 97-4051, 1997.
9. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy. a systematic review and meta-analysis Acta Intern Med. 159:1999;941-955.
10. Cumming R.G., Mitchell P., Leeder S.R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 337:1997;8-14.
11. Koda A., Yanagihara Y., Matsuura N. IPD-1151T. a prototype drug of IgE antibody synthesis modulation Agents Actions Suppl. 34:1991;369-378.
12. Yamaya H., Basaki Y., Togawa M., Kojima M., Kiniwa M., Matsuura N. Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents. Life Sci. 19:1995;1647-1654.
13. Yanagihara Y., Kiniwa M., Ikizawa K., Sida T., Matsuura N., Koda A. Suppression of IgE production by IPD-1151T (suplatast tosilate). a new dimethylsulfonium agent: (2) Regulation of human IgE response Jpn J Pharmacol. 61:1993;31-39.
14. Sano Y., Miyamoto T., Makino S. Anti-inflammatory effect of suplatast tosilate on mild asthma. Chest. 112:1997;862-863.
15. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
16. Neukirch F., Liard R., Segala C., Korobaeff M., Henry C., Cooreman J. Peak expiratory flow variability and bronchial responsiveness to methacholine. an epidemiologic study in 117 workers Am Rev Respir Dis. 146:1992;71-75.
17. Karp-Wills M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 17:1999;255-281.
18. Haahtela T., Järvinen M., Kava T.et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 331:1994;700-705.
19. Spence D.P.S., Johnston S.L., Calverley P.M.A.et al. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am J Respir Crit Care Med. 149:1994;1142-1148.
20. Bianco S., Vaghi A., Robuschi M., Refini R.M., Pieroni M.G., Sestini P. Steroid-sparing effect of inhaled lysine acetylsalicylate and furosemide in high-dose beclomethasone-dependent asthma. J Allergy Clin Immunol. 95:1995;937-943.
21. Sugai T., Sakiyama Y., Matsumoto S. Eosinophil cationic proteins in peripheral blood of pediatric patients with allergic diseases. Clin Exp Allergy. 22:1992;275-281.
22. Mullarkey M.F., Blumenstein B.A., Andrade P., Bailey G.A., Olason I., Wetzel C.E. Methotrexate in the treatment of corticosteroid-dependent asthma. a double-blind crossover study N Eng J Med. 318:1988;603-607.
23. Alexander A.G., Barnes N.C., Kay A.B. Trial of cyclosporin in corticosteroid dependent chronic severe asthma. Lancet. 339:1992;324-388.